← Back to headlines
Oncolytics Biotech Concludes Enrollment for GIT Cancer Trial
Oncolytics Biotech has announced the conclusion of enrollments for its clinical trial targeting gastrointestinal (GIT) cancer, leading to gains for the company.
24 Feb, 19:45 — 24 Feb, 19:45
ℹOnly 1 source covers this story
Read at source (1 outlet)
Related Stories
Sleep Apnoea Costs UK Businesses Billions Annually
18m ago
Expert Discusses Statins' Side Effects, Including Dementia and Erectile Dysfunction
49m ago
Care Facilities Revert to Paper After MediMap Hack
1h ago
Arvinas outlines 2026 clinical data milestones and maintains cash runway into second half of 2028 amid strategic pipeline focus
1h ago